INT71164

Context Info Confidence 0.59 First Reported 1997 Last Reported 2010 Negated 1 Speculated 0 Reported most in Body Documents 7 Total Number 9 Disease Relevance 4.78 Pain Relevance 0.04

mitochondrion (PDSS1)

Anatomy Link Frequency colon 1 PDSS1 (Homo sapiens)

Pain Link Frequency Relevance Heat medulla 1 73.92 Inflammation 10 44.52 headache 7 25.00 positron emission tomography 6 5.00 Angina 5 5.00 alcohol 5 5.00 corticosteroid 3 5.00 Paresthesia 3 5.00 backache 3 5.00 addiction 3 5.00

Disease Link Frequency Relevance Heat Syndrome 134 100.00 Coronary Artery Disease 25 99.60 Breast Cancer 5 99.40 Disease 91 98.56 Stress 11 98.04 Colon Cancer 3 98.02 Vasovagal Syncope 6 97.24 Anaemia 24 95.76 Leukopenia 3 95.20 Thrombocytopenia 36 94.32

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

As TPT progressed, the magnitude and lability of CV responses as well as frequency of VVS were reduced.

Gene_expression (progressed) of TPT associated with vasovagal syncope

1) Confidence 0.59 Published 1997 Journal Clin. Auton. Res. Section Abstract Doc Link 9292245 Disease Relevance 0.56 Pain Relevance 0.04

For instance, we detected Dps, a DNA-binding protein that protects DNA during stress; Daigle et al. also identified dps using selective capture of transcribed sequence (SCOTS) technology to analyze S.

Gene_expression (detected) of Dps associated with stress

2) Confidence 0.25 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2736619 Disease Relevance 0.26 Pain Relevance 0

Instructions for the patient need to include information about the symptoms of PDSS, the avoidance of driving or operating machinery.20

Gene_expression (symptoms) of PDSS associated with syndrome

3) Confidence 0.22 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2898165 Disease Relevance 0.43 Pain Relevance 0

However, 2 patients treated with olanzapine LAI experienced PDSS following possible inadvertent intravascular injection.

Gene_expression (experienced) of PDSS associated with syndrome

4) Confidence 0.22 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2898165 Disease Relevance 0.39 Pain Relevance 0

The combination PLD/weekly PTX was well tolerated, as was the PLD/vinorelbine combination. 104 In contrast, PLD/TPT, even if tested at different doses of the two drugs, was characterized by an unacceptable rate of severe anemia (48%), leukopenia (70%), and thrombocytopenia (44%).102 PLD: phase III studies

Gene_expression (/) of TPT associated with anaemia, leukopenia and thrombocytopenia

5) Confidence 0.11 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2952486 Disease Relevance 0.75 Pain Relevance 0

More mature survival analysis confirmed the long-term advantage for platinum-sensitive patients receiving PLD vs TPT (median OS = 27 months vs 17.5 months, hazard ratio [HR] = 1.432, P value = 0.017).108 Moreover, for partially platinum-sensitive disease (n = 122), the HR favored PLD vs TPT (HR = 1.58, P value = 0.021).

Gene_expression (receiving) of TPT associated with disease

6) Confidence 0.09 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2952486 Disease Relevance 0.66 Pain Relevance 0

At this time, available data support the phase II-derived suggestions that in platinum-resistant disease none of the currently most frequently used drugs, such as PLD, GEM, or TPT, shows superiority over the others in terms of response rate and survival; in this context the 3-week schedule of administration of PLD at 40 mg/m2 seems to offer the most favorable toxicity profile, which is likely to sustain the achievement of better QoL scores, at least in comparison to GEM.110

Neg (none) Gene_expression (shows) of TPT associated with toxicity and disease

7) Confidence 0.09 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2952486 Disease Relevance 0.56 Pain Relevance 0

Associations of increased intakes and/or in vivo levels of industrially-produced trans FAs with CHD risk are well established [29], whereas little information exists for eicosadienoic acid.

Gene_expression (produced) of trans associated with coronary artery disease

8) Confidence 0.06 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2673680 Disease Relevance 0.31 Pain Relevance 0

Modulation of p53 expression by red wine and its polyphenolic contents was studied on three human breast cancer cell lines and one colon cancer line by Soleas et al. (2001), which showed that these polyphenols, including quercetin, catechin, trans-resveratrol and caffeic acid did not affect p53 gene expression in two of the breast cancer lines.

Gene_expression (expression) of trans in colon associated with colon cancer and breast cancer

9) Confidence 0.01 Published 2009 Journal Phytochem Rev Section Body Doc Link PMC2928446 Disease Relevance 0.87 Pain Relevance 0

General Comments

This test has worked.